Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione

{
  "publication_number": "US9913801B2",
  "country": "US",
  "kind": "B2",
  "title": "Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione",
  "abstract": "The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.",
  "claims": [
    "1. A method of measuring the effectiveness of treatment of a patient using liposomal reduced glutathione in combination with an antibiotic against an antibiotic-resistant bacteria normally treated by said antibiotic, comprising the following steps: initially measuring TGF-β in the blood plasma of a patient; if TGF-beta is above a normal level administering, to a patient having disease symptoms arising from anti-biotic resistant strains of bacteria of Klebsiella pneumoniae, intravenously and thereafter if patient compliance can be assured, orally, a dose of a reduced glutathione stabilized and encapsulated in a liposomal pharmaceutical carrier capable of being ingested orally, and capable of delivering glutathione (reduced) in a physiologically active state to improve symptoms in disease states by transfer of the glutathione into animal cells, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; simultaneously administering the course of antibiotic through the recommended course of administration of said antibiotic; measuring the reduction of elevated TGF-β in blood plasma; measuring whether the level of said bacteria has fallen; and thereafter continuing to administer said glutathione and re-measuring said level of said bacterial until normal bodily health is achieved.",
    "2. The method according to claim 1, further comprising the following step: administering Vitamin D."
  ],
  "description_excerpt": "Priority is claimed from U.S. Provisional Applications 61/765,379 filed Feb. 15, 2013 and 61/767,474 filed Feb. 21, 2013.\n\nThe invention relates to the use of liposomally formulated reduced glutathione to treat anti-biotic resistant diseases having evolving bacterial resistance.\n\nKlebsiella pneumonia is a growing issue in intensive care units as it is a common bacterial contaminant that has become relatively refractory to current treatment regimes. Additionally, because Klebsiella tends to be omnipresent in the body, though well controlled, the intensive care unit of a hospital or medical care facility functions as an incubator for strains of Klebsiella that have shown an increasing pattern of producing ever more antibiotic resistant strains of Klebsiella pneumoniae in patients. Further those strains appear to have a gene characteristic that enables the transfer of the increased antibiotic resistance to other virulent and more widespread diseases which this invention is also designed to curtail.\n\nMore broadly, the invention applies to anti-biotic resistant strains of bacteria selected from the family groups of Klebsiella, Staphylococcus, Clostridium, Shigella, Pneumonia, Escheria coli, Chlamydia, and Anthrax, and a parasitic disease Leishmaniasis on the same principle because strains of these diseases also have the ability to evolve their resistance to antibiotic treatment.\n\nThe technical problem is finding and enabling a composition to diminish the growth of Klebsiella pneumonia cultures in the patient's body, particularly in lung tissue, and both bacterial and viral pneumonia more generally.",
  "cpc": [
    "A61K 9/127",
    "A61K 2300/00",
    "A61K 31/407",
    "A61K 31/43",
    "A61K 31/59",
    "A61K 38/063",
    "A61K 45/06",
    "A61K 9/0095",
    "A61K 9/4858",
    "A61P 31/00",
    "A61P 31/04",
    "C12Q 1/06",
    "C12Q 1/18",
    "G01N 2800/52",
    "Y02A 50/30"
  ],
  "ipc": [
    "A61K 31/59",
    "A61K 38/06",
    "A61K 45/06",
    "A61K 9/127",
    "C12Q 1/18",
    "A61K 31/407",
    "A61K 31/43",
    "A61K 9/00",
    "A61K 9/48",
    "C12Q 1/06"
  ],
  "assignees": [
    "Your Energy Systems LLC"
  ],
  "inventors": [
    "Frederick Timothy Guilford"
  ],
  "filing_date": "2013-03-15",
  "publication_date": "2018-03-13",
  "grant_date": "2018-03-13",
  "priority_date": "2013-02-15",
  "application_number": "US-201314768007-A",
  "family_id": "51354458",
  "cited_by_count": 1,
  "citations": [
    "WO2007030492A2"
  ]
}